Serina Therapeutics's 15min chart shows MACD Death Cross and KDJ Death Cross signals.
ByAinvest
Wednesday, Sep 3, 2025 1:48 pm ET1min read
SER--
A MACD Death Cross occurs when the MACD line crosses below the signal line, signaling a potential reversal in the trend. Similarly, a KDJ Death Cross happens when the K line crosses below the D line on the KDJ indicator, suggesting a bearish trend. The Bearish Marubozu pattern, characterized by a single candlestick with no upper or lower wick, further supports this bearish sentiment.
The combination of these technical indicators suggests that sellers currently control the market, and there is a high likelihood of continued bearish momentum. This development comes amidst positive analyst ratings for SER, with Healthequity providing a Buy rating with a $15.00 price target [2].
Serina Therapeutics, a biotechnology company developing drugs to treat neurological diseases and pain, has been making strides in its clinical trials. Its lead product candidate, SER 252, a POZ conjugate for the treatment of advanced Parkinson's disease, has completed phase 1a clinical trials. Additionally, the company is developing POZ technology in lipid nanoparticle delivered RNA vaccines for infectious diseases [3].
Despite these promising developments, the technical indicators point to a potential downward trend in the stock price. Investors should closely monitor the market and consider the implications of these technical signals when making investment decisions.
References:
[1] https://finance.yahoo.com/quote/SER/
[2] https://www.ainvest.com/news/healthequity-hqy-maintains-outperform-rating-barrington-research-125-price-target-2508/
[3] https://www.ainvest.com/news/serina-therapeutics-soars-28-55-fda-trial-design-approval-2508/
The 15-minute chart for Serina Therapeutics has triggered a MACD Death Cross, a KDJ Death Cross, and a Bearish Marubozu pattern at 13:45 on September 3, 2025. This suggests that the stock price has the potential to continue falling, with a shift in momentum towards the downside and a potential further decrease in value. Sellers currently control the market, and there is a high likelihood of continued bearish momentum.
On September 3, 2025, Serina Therapeutics, Inc. (SER) experienced a significant shift in its stock price dynamics, as technical indicators suggested a potential downward trend. The 15-minute chart for SER triggered a MACD Death Cross, a KDJ Death Cross, and a Bearish Marubozu pattern at 13:45. These indicators, widely used by traders to gauge momentum and trend direction, indicate a shift towards bearish momentum [1].A MACD Death Cross occurs when the MACD line crosses below the signal line, signaling a potential reversal in the trend. Similarly, a KDJ Death Cross happens when the K line crosses below the D line on the KDJ indicator, suggesting a bearish trend. The Bearish Marubozu pattern, characterized by a single candlestick with no upper or lower wick, further supports this bearish sentiment.
The combination of these technical indicators suggests that sellers currently control the market, and there is a high likelihood of continued bearish momentum. This development comes amidst positive analyst ratings for SER, with Healthequity providing a Buy rating with a $15.00 price target [2].
Serina Therapeutics, a biotechnology company developing drugs to treat neurological diseases and pain, has been making strides in its clinical trials. Its lead product candidate, SER 252, a POZ conjugate for the treatment of advanced Parkinson's disease, has completed phase 1a clinical trials. Additionally, the company is developing POZ technology in lipid nanoparticle delivered RNA vaccines for infectious diseases [3].
Despite these promising developments, the technical indicators point to a potential downward trend in the stock price. Investors should closely monitor the market and consider the implications of these technical signals when making investment decisions.
References:
[1] https://finance.yahoo.com/quote/SER/
[2] https://www.ainvest.com/news/healthequity-hqy-maintains-outperform-rating-barrington-research-125-price-target-2508/
[3] https://www.ainvest.com/news/serina-therapeutics-soars-28-55-fda-trial-design-approval-2508/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet